Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adul
Go back to Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adul| Gilead Sciences (NASDAQ: GILD) | Delayed: 151.00 -0.22 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.22 | 52 Week High | $108.63 | |||
| Open | $149.23 | 52 Week Low | $71.39 | |||
| Day High | $151.19 | P/E | 83.43 | |||
| Day Low | $149.23 | EPS | $1.81 | |||
| Volume | 6,181,813 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 150.33 -2.01 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $152.34 | 52 Week High | $65.46 | |||
| Open | $150.83 | 52 Week Low | $47.97 | |||
| Day High | $152.22 | P/E | 102.27 | |||
| Day Low | $150.09 | EPS | $1.47 | |||
| Volume | 4,397,470 | |||||
